Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IGXTNASDAQ:VIGLNASDAQ:VTYXNASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AVIGLVigil Neuroscience$7.88-0.1%$2.67$1.31▼$7.95$367.54M1.9652,546 shs595,256 shsVTYXVentyx Biosciences$1.75-3.6%$1.24$0.78▼$5.66$124.18M0.731.33 million shs348,595 shsVXRTVaxart$0.45-4.8%$0.40$0.29▼$1.07$101.56M1.272.42 million shs518,739 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%VIGLVigil Neuroscience-0.13%0.00%+310.42%+225.62%+165.32%VTYXVentyx Biosciences+2.26%-0.55%+41.41%+14.56%-63.29%VXRTVaxart+3.84%-0.57%+9.90%-8.25%-43.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXTIntelGenx Technologies0.2457 of 5 stars0.03.00.00.00.61.70.0VIGLVigil Neuroscience3.1634 of 5 stars4.03.00.00.02.32.50.6VTYXVentyx Biosciences3.1416 of 5 stars3.43.00.00.04.12.50.6VXRTVaxart1.9901 of 5 stars3.51.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx Technologies 0.00N/AN/AN/AVIGLVigil Neuroscience 2.00Hold$10.8037.14% UpsideVTYXVentyx Biosciences 2.75Moderate Buy$10.00473.07% UpsideVXRTVaxart 3.00Buy$3.00574.16% UpsideCurrent Analyst Ratings BreakdownLatest IGXT, VIGL, VXRT, and VTYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/22/2025VIGLVigil NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.003/27/2025VXRTVaxartB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $2.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39VIGLVigil NeuroscienceN/AN/AN/AN/A$3.24 per shareN/AVTYXVentyx BiosciencesN/AN/AN/AN/A$4.13 per shareN/AVXRTVaxart$47.40M2.14N/AN/A$0.38 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AVIGLVigil Neuroscience-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)VTYXVentyx Biosciences-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%8/14/2025 (Estimated)VXRTVaxart-$82.46M-$0.27N/AN/AN/A-431.61%-110.46%-62.78%8/14/2025 (Estimated)Latest IGXT, VIGL, VXRT, and VTYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48-$0.39+$0.09-$0.39N/AN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A3/20/2025Q4 2024VXRTVaxart-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million3/13/2025Q4 2024VIGLVigil Neuroscience-$0.49-$0.57-$0.08-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/AN/AN/AVIGLVigil NeuroscienceN/A3.723.72VTYXVentyx BiosciencesN/A23.5223.52VXRTVaxartN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/AVIGLVigil Neuroscience83.64%VTYXVentyx Biosciences97.88%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%VIGLVigil Neuroscience18.01%VTYXVentyx Biosciences14.49%VXRTVaxart2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableVIGLVigil Neuroscience4046.67 million27.38 millionNot OptionableVTYXVentyx Biosciences3071.16 million57.86 millionOptionableVXRTVaxart120228.22 million221.57 millionOptionableIGXT, VIGL, VXRT, and VTYX HeadlinesRecent News About These CompaniesVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29 at 4:05 PM | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29 at 8:32 AM | quiverquant.comVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - What's Next?May 29 at 5:10 AM | marketbeat.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28 at 3:41 PM | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Head to Head ContrastMay 28 at 2:07 AM | americanbankingnews.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Raised to Hold at Wall Street ZenMay 25, 2025 | americanbankingnews.comWall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"May 24, 2025 | marketbeat.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 SharesMay 20, 2025 | insidertrades.comVaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder MeetingMay 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What HappenedMay 16, 2025 | marketbeat.comVaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 15, 2025 | globenewswire.comVaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational MedicineMay 14, 2025 | globenewswire.comVaxart Names Grasman as CFO, Succeeding LeeMay 14, 2025 | marketwatch.comVaxart, Inc. (VXRT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGXT, VIGL, VXRT, and VTYX Company DescriptionsIntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Vigil Neuroscience NASDAQ:VIGL$7.88 -0.01 (-0.06%) As of 12:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Ventyx Biosciences NASDAQ:VTYX$1.74 -0.07 (-3.59%) As of 12:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.Vaxart NASDAQ:VXRT$0.44 -0.02 (-4.77%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
